Characteristics of lipid micro- and nanoparticles based on supercritical formation for potential pharmaceutical application

Table 2 Available works on the production of solid lipid particles by supercritical fluid technology

Method	Lipid composition	Active ingredient	Particle size	Ref
Supercritical fluid-based coating	Gelucire^® 50/02	Bovine serum albumin	125 to 500 μm	[58]
Supercritical fluid-based coating	Trimyristin	Bovine serum albumin	~50 μm	[58]
Supercritical fluid extraction of emulsions	Gelucire^® 50/13, tripalmitin, or tristearin	Indomethacin or ketoprofen	~30 nm	[59]
Supercritical co-injection process	Precirol^® ATO 5	Pseudoephedrine chlorhydrate or bovine serum albumin	~60 μm	[60]
Particles from gas-saturated solutions	Hydrogenated palm oil	Theophylline	~3 μm	[61]
	Glycerylmonostearate	Caffeine	~5 μm	[62]
	Glycerylmonostearate and Cutina^® HR	Caffeine, glutathione, or ketoprofen	NM	[63]
	Precirol^® ATO 5 and/or Gelucire^® 50/13	Trans-chalcone	1 to 6 μm	[64]
	Glycerylmonostearate and Cutina^® HR	Ketoprofen	NM	[65]
	Precirol^® ATO 5	Ascorbic acid	~2 μm
	Myristic acid or tripalmitin	Ibuprofen	2 to 4 μm	[66]
	Beeswax	Menthol	~2 to 50 μm	[67]
	Ceramide 3A, cholesterol, and Radiacid^®	-	200 to 500 nm	[68]
	Tristearin and Epikuron 200^®	Insulin or recombinant human growth hormone	~197 nm	[69]
	Tristearin and Epikuron 200^® or tristearin, Epikuron 200, and PEG	Insulin	80 to 120 nm	[70]
	Tristearin, Epikuron 200^®, and oleic acid	Magnetite nanoparticles	200 to 800 nm	[71]
	Tristearin and Epikuron 200^®	Ribonuclease A functionalized or not with PEG₅₀₀₀	4 to 13 μm	[72]